Department of Pathology, Division of Anatomic Pathology, University of Alabama at Birmingham, Birmingham, AL, USA.
Cancer Biomark. 2010;9(1-6):21-39. doi: 10.3233/CBM-2011-0172.
Invasive tumors (cancers or malignant lesions) typically develop in the setting in which there is the presence of putative non-invasive lesions and the development of these non-invasive lesions frequently precedes the development of cancers. For some organs, such as the oral cavity, cervix and skin, the respective putative pre-invasive lesions can be observed over time and documented to progress to invasive lesions. However, for less readily observable lesions, such as those of the prostate, the progression of the pre-invasive lesions, e.g., prostatic intraepithelial neoplasia (PIN) and prostatic proliferative inflammatory atrophy (PIA) to prostatic cancer are more difficult to document. Thus, for most organ systems, specific pre-invasive neoplastic lesions have been proposed based upon the apparent observations of one or more of the following: 1) microinvasive disease developing from a pre-invasive neoplastic lesion, 2) the general association of the pre-invasive lesion with invasive lesions, 3) the subsequent development of invasive lesions following diagnosis of the pre-invasive lesion, 4) correlations of the molecular features of the putative pre-invasive lesion with the matching invasive lesions, and 5) reductions in the rate of cancer following removal of the pre-invasive lesion. When there are mixtures of pre-invasive lesions with actual cancers in the same case, some of the above specific associations are more difficult to make. Several terms have been used to describe pre-invasive lesions, many of which are now less useful as our knowledge of these lesions increases. It is now commonly accepted that these lesions are a features of the spectrum of neoplastic development and most are accepted as ``neoplastic lesions'' with associated molecular features, even though they may be reversible even if they have mutations in suppressor genes (e.g., p53) or are associated with viral etiologies (e.g., cervical intraepithelial neoplasia). The overall term, "pre-invasive neoplasia", seems to best describe these putative pre-invasive lesions. Thus, terms such as incipient neoplasia should be abandoned. The term "intra-epithelial neoplasia" with an associated grade, which has been developed for pre-invasive neoplastic lesions of the cervix, i.e. cervical intraepithelial neoplasia (CIN), seems to be a terminology that adds consistency across epithelial organs. Thus, adoption of these terms for the additional organ sites of pancreas (PanIN) and prostate (PIN) seems accepted. Less descriptive terms such as the degrees of dysplasia of the oral cavity and bronchopulmonary system and actinic keratosis and Bowen's disease of the skin might be better designated as oral intraepithelial neoplasia (OIN), pulmonary intraepithelial neoplasia (PulIN) and dermal intraepithelial neoplasia (DIN). The etiology of pre-invasive neoplasia is the etiology of the matching cancers. Some obvious initiating factors include exposure to the whole range of ionizing and non-ionizing radiation, tobacco abuse and a broad range of other carcinogens (e.g., benzene). A frequent initiation factor is the setting of long standing continuing damage, inflammation and repair (LOCDIR) which leads to early molecular features associated with neoplasia after about one year. An excellent example of this is ulcerative colitis (UC) in which dysregulation of microsatellite repair enzymes have been documented one year following diagnosis of UC. While the nomenclature, description, diagnosis and etiology of pre-invasive neoplasia has advanced, approaches to therapy of such lesions have not progressed adequately even though it has been identified that, for example, removal of polyps periodically from the colorectum, DCIS from the breast, and high grade CIN from the cervix, results in a reduction in the development of cancers of the colorectum, breast, and cervix, respectively. With the development of more molecularly targeted therapy with fewer side effects, preventive therapies may be more successfully targeted to pre-invasive neoplastic lesions.
侵袭性肿瘤(癌症或恶性病变)通常在存在疑似非侵袭性病变的情况下发展,而这些非侵袭性病变的发展通常先于癌症的发生。对于某些器官,如口腔、宫颈和皮肤,相应的疑似前病变可以随着时间的推移被观察到,并记录为进展为侵袭性病变。然而,对于较难观察到的病变,如前列腺,前病变(如前列腺上皮内瘤变(PIN)和前列腺增生性炎症萎缩(PIA))向前列腺癌的进展更难记录。因此,对于大多数器官系统,基于以下一种或多种明显观察结果,提出了特定的前肿瘤性病变:1)从前肿瘤性病变发展而来的微侵袭性疾病,2)前病变与侵袭性病变的一般关联,3)在前病变诊断后侵袭性病变的后续发展,4)推测前病变的分子特征与匹配的侵袭性病变的相关性,以及 5)在前病变切除后癌症发生率的降低。当同一病例中既有前病变又有实际癌症时,上述某些特定关联就更难做出。已经使用了几个术语来描述前病变,随着我们对这些病变认识的提高,其中许多术语现在已经不太有用了。现在普遍认为,这些病变是肿瘤发展谱的一个特征,大多数病变被认为是具有相关分子特征的“肿瘤性病变”,即使它们可能具有抑癌基因(如 p53)的突变,或者与病毒病因(如宫颈上皮内瘤变)有关。总的来说,“前肿瘤性病变”这个术语似乎最能描述这些疑似前肿瘤性病变。因此,“初发肿瘤”等术语应该被废弃。术语“上皮内肿瘤”及其相关分级,已经为宫颈前肿瘤性病变(即宫颈上皮内瘤变(CIN))所开发,似乎是一种在整个上皮器官中增加一致性的术语。因此,似乎已经接受了将这些术语用于胰腺(PanIN)和前列腺(PIN)等其他器官部位。口腔和支气管肺系统的异型增生程度以及皮肤的光化性角化病和 Bowen 病等不太具描述性的术语可能更好地指定为口腔上皮内肿瘤(OIN)、肺上皮内肿瘤(PulIN)和皮肤上皮内肿瘤(DIN)。前肿瘤性病变的病因也是相应癌症的病因。一些明显的起始因素包括接触各种电离和非电离辐射、滥用烟草以及广泛的其他致癌物质(如苯)。一个常见的起始因素是长期持续损伤、炎症和修复(LOCDIR),它会导致大约一年后与肿瘤发生相关的早期分子特征。溃疡性结肠炎(UC)就是一个很好的例子,在 UC 诊断后一年,已经记录到微卫星修复酶的失调。虽然前肿瘤性病变的命名法、描述、诊断和病因学已经取得了进展,但这些病变的治疗方法并没有得到充分的发展,尽管已经确定,例如,定期从结肠直肠切除息肉、从乳房切除 DCIS(导管原位癌),以及从宫颈切除高级别 CIN,分别会降低结直肠、乳房和宫颈癌症的发生。随着更具分子靶向性和更少副作用的治疗方法的发展,预防性治疗可能更有针对性地针对前肿瘤性病变。